LIN28A gene polymorphisms modify neuroblastoma susceptibility: A four-centre case-control study

Rui-Xi Hua1,2 | Zhenjian Zhuo1 | Lili Ge3 | Jinhong Zhu1,4 | Li Yuan1 | Chongfen Chen3 | Jing Liu3 | Jiwen Cheng5 | Haixia Zhou6 | Jiao Zhang7 | Huimin Xia1,8 | Xianwei Zhang8 | Jing He1

1Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China
2Department of Oncology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
3Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children's Hospital, Zhengzhou, China
4Department of Clinical Laboratory, Biobank, Harbin Medical University Cancer Hospital, Harbin, China
5Department of Pediatric Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
6Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China
7Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
8Department of Pediatric Oncologic Surgery, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China

Correspondence
Jing He, Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou 510623, Guangdong, China. Email: hejing198374@gmail.com
Xianwei Zhang, Department of Pediatric Oncologic Surgery, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, 33 Longhu Waihuan East Road, Zhengzhou 450018, Henan, China. Email: zhangxw956658@163.com.

Funding information
Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Grant/Award Number: 2019B030303004; Pearl River S&T Nova Program of Guangzhou, Grant/Award Number: 201710010086

Abstract
Neuroblastoma ranks the most common seen solid tumour in childhood. Overexpression of LIN28A gene has been linked to the development of multiple human malignancies, but the relationship between LIN28A single nucleotide polymorphisms (SNPs) and neuroblastoma susceptibility is still under debate. Herein, we evaluated the correlation of four potentially functional LIN28A SNPs (rs3811464 G>A, rs3811463 T>C, rs34787247 G>A, and rs11247957 G>A) and neuroblastoma susceptibility in 505 neuroblastoma patients and 1070 controls from four independent hospitals in China. The correlation strengths were determined by using odds ratios (ORs) and corresponding 95% confidence intervals (CIs). Among these SNPs, rs34787247 G>A exhibited a significant association with increased susceptibility in neuroblastoma (GA vs GG: adjusted OR = 1.30, 95% CI = 1.03-1.64; AA vs GG: adjusted OR = 2.51, 95% CI = 1.36-4.64, AA/GA vs GG: adjusted OR = 1.42, 95% CI = 1.12-1.80, AA vs GG/GA: adjusted OR = 2.39, 95% CI = 1.29-4.42). Furthermore, the combined analysis of risk genotypes revealed that subjects carrying three risk genotypes (adjusted OR = 1.64, 95% CI = 1.02-2.63) are more inclined to develop neuroblastoma than those without risk genotype, and so do carriers of 1-4 risk genotypes.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
INTRODUCTION

Neuroblastoma is a solid tumour that predominantly affects infants and young children. It mainly develops from neural crest progenitor cells. Neuroblastoma constitutes about 8%-10% of all paediatric cancers, but disproportionately causes 12%-15% cancer death in children. Neuroblastoma displays considerable clinical heterogeneity, ranging from spontaneous recovery to therapy-refractory progression. The distinct difference in survival rate among subgroups was another reflection of such heterogeneity. Patients with neuroblastoma can be classified into three risk groups: low risk, intermediate risk and high risk by using some clinical and biological prognostic factors. Patients with a non-high risk (low and intermediate risk) of neuroblastoma have a long-term survival rate up to 90% or above, while those with high risk of neuroblastoma only achieve a survival rate as low as 40%.

In recent decades, remarkable advancement has been achieved in comprehending the fundamental aetiology of neuroblastoma. Children’s and pregnant women’s exposures to many environmental factors were reported to predispose to neuroblastoma, yet the causality could not be finally confirmed. On the other hand, genetic alterations have been shown to be linked to neuroblastoma susceptibility. Mutations in genes ALK, PHOX2B are frequently observed in hereditary neuroblastoma. Moreover, a number of single nucleotide polymorphisms (SNPs) in association with neuroblastoma predisposition have been identified in genes recently, including TP53, LIN28B, HACE1, LMO1, BARD1, NEFL and CDKN1B. Moreover, a fine-mapping analysis of BARD1 locus (2q35) also identified two independent genome-wide neuroblastoma-associated loci. However, the present identified genetic variations could not fully account for the carcinogenesis of neuroblastoma. We are still on the discovery journey of unveiling more causative genetic alterations hidden in the bush.

LIN28 is a conserved RNA-binding protein that plays a significant part in the regulation of cell proliferation, glucose metabolism and pluripotency through interacting with miRNAs. The mammalian genome, LIN28 gene, encodes two Lin28 paralogs, Lin28A and Lin28B. LIN28A inhibits the maturation process of let-7 microRNAs and thereby enhances the translation of let-7 target mRNAs. Briefly, cytoplasmic LIN28A induces pre-let-7 oligo-uridylation through a TUTase-dependent mechanism. Such poly-uridylation leads to pre-let-7 instability and eventually reduces the amount of mature let-7. let-7 is a tumour suppressor. Its downregulation promotes tumorigenesis and correlates with poor prognosis. By binding to a variety of mRNA targets, LIN28A also has additional functions except for suppressing let-7 maturation.

Over-activation of the LIN28A gene has been observed in various human cancers. The mechanism of the LIN28A-mediated tumorigenesis has been extensively investigated. However, the implications of LIN28A gene SNPs in neuroblastoma risk remain undiscovered. To determine the relationship between LIN28A gene SNPs and neuroblastoma susceptibility, we performed this multi-centre epidemiological study.

MATERIALS AND METHODS

Study subjects

The current case-control study included 505 cases and 1070 healthy non-cancer controls, as noted previously (Table S1). Cases were newly diagnosed and histologically confirmed with neuroblastoma. Frequency-matched controls on age and sex were recruited from the same residing area as cases. Without no exception, every participant provided his/her necessary written informed consent. Demographic information was gathered up by trained interviewers. The complete criterion for selecting participants was addressed in our previous work. This study has gained its approval from the institutional review boards constituted by all participating hospitals including Guangzhou Women and Children’s Medical Center, the First Affiliated Hospital of Zhengzhou University, the Second Affiliated Hospital of Xi’an Jiaotong University, and The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University.

Polymorphism selection and genotyping

We retrieved four SNPs with potential function in the LIN28A gene from the dbSNP database and SNPinfo software. Selection
criteria were briefly described below: (a) the minor allele frequency reported in HapMap was >5% for Chinese Han subjects; (b) putative functional potentials SNPs located in the 5'-flanking region, exon, 5'-untranslated region (UTR) and 3' UTR, which might affect transcription activity or binding capacity of the microRNA binding site; and (c) SNPs in low linkage disequilibrium (LD) with each other ($R^2 < 0.8$). There was no significant LD ($R^2 < 0.8$) among these four SNPs of LIN28A ($R^2 = 0.183$ between rs3811464 and rs3811463, $R^2 = 0.009$ between rs3811464 and rs34787247, $R^2 = 0.054$ between rs3811464 and rs11247957; $R^2 = 0.03$ between rs3811463 and rs34787247, $R^2 = 0.052$ between rs3811463 and rs11247957; $R^2 = 0.002$ between rs34787247 and rs11247957) (Figure S1). The locations of these SNPs in the LIN28A are as below: rs3811464 G>A in the upstream, rs3811463 T>C, rs34787247 G>A, and rs11247957 G>A are all in the 3' UTR. More detailed selection standards were exhibited at our previous work.38 DNA was isolated from the blood sample using a TIANamp Blood DNA Kit (TianGen Biotech Co. Ltd.). Then, the DNA was further performed to genotype using the TaqMan methodology instructed by the manufacturers.40-42 Negative controls (water samples) were used to ensure genotyping preciseness. A repeated genotyping of 10% randomly selected sample was also conducted in all plates with concordance rates of 100%.

2.3 | Statistical analysis

The $\chi^2$ test was applied to test the difference in the distributions of subject characteristics between the cases and controls. A goodness-of-fit chi-squared test was adopted to find whether there exists Hardy-Weinberg equilibrium (HWE) among controls. Logistic regression analysis was applied to detect any association with neuroblastoma risk, with the crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs). The adjusted ORs were with neuroblastoma risk, with the crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs). The adjusted ORs were

3 | RESULTS

3.1 | The relationship between LIN28A SNPs and neuroblastoma susceptibility

The association of all variant genotypes of the four LIN28A SNPs (rs3811464 G>A, rs3811463 T>C, rs34787247 G>A, rs11247957 G>A) with neuroblastoma risk is shown in Table 1 for combined subjects and in Table S2 for divided subjects. All these SNPs in controls were in accordance with HWE (all with an HWE $P > .05$). In the single-locus analysis, only one variant, rs34787247 G>A, in the LIN28A gene could significantly influence neuroblastoma susceptibility. Carriers of rs34787247A allele showed increased susceptibility to neuroblastoma (GA vs GG: adjusted OR = 1.30, 95% CI = 1.03-1.64, $P = .027$; AA vs GG: adjusted OR = 2.51, 95% CI = 1.36-4.64, $P = .003$; AA/GA vs GG: adjusted OR = 1.42, 95% CI = 1.12-1.80, $P = .004$; AA vs GG/AA: adjusted OR = 2.39, 95% CI = 1.29-4.42, $P = .006$). The rs3811464 GA/AA, rs3811463 TC/CC, rs34787247 GA/AA and rs11247957 GA/AA are treated as risk genotypes. Then, we analysed the combined effect of risk genotypes and observed that participants with 3 or 1-4 risk genotypes experienced a 1.64-fold (adjusted OR = 1.64, 95% CI = 1.02-2.63, $P = .04$) and 1.26-fold (adjusted OR = 1.26, 95% CI = 1.01-1.56, $P = .04$) increase in the risk of developing neuroblastoma, respectively.

3.2 | Stratification analysis

Table 2 displays the contents of the association between LIN28A gene polymorphisms and susceptibility to neuroblastoma in certain groups separated by age, gender, sites of origins and clinical stages. We detected the rs3811464 AA genotypes carriers were more likely to have increased neuroblastoma risk in the subgroup of tumours in retroperitoneal (adjusted OR = 2.23, 95% CI = 1.04-4.81, $P = .041$). As for rs34787247 polymorphism, compared to its GG genotype, stronger risk effect of GA/AA genotypes was found among children ≤18 month (adjusted OR = 1.51, 95% CI = 1.04-2.19, $P = .031$), > 18 month (adjusted OR = 1.38, 95% CI = 1.01-2.87, $P = .042$), males (adjusted OR = 1.47, 95% CI = 1.08-2.01, $P = .015$) and patients at clinical stages of III + IV (adjusted OR = 1.43, 95% CI = 1.05-1.97, $P = .025$). Besides, the combined analysis stated that the 1-4 risk genotypes had an enhanced neuroblastoma risk in the patients with tumour in retroperitoneal (adjusted OR = 1.44, 95% CI = 1.00-2.07, $P = .048$) and subgroup at early clinical stages I + II + 4S (adjusted OR = 1.44, 95% CI = 1.08-1.91, $P = .014$).
We further determined whether the haplotypes of the four LIN28A SNPs were linked to neuroblastoma risk. As shown in Table 3, the haplotype consisting of wild-type alleles (GTGG) was defined as the reference group. We detected a significant elevated neuroblastoma risk in subjects with haplotypes GTAG (adjusted OR = 1.35, 95% CI = 1.07-1.72, P = .012) and ACAG (adjusted OR = 3.20, 95% CI = 1.41-7.25, P = .005).
### TABLE 2  Stratification analysis of risk genotypes with neuroblastoma susceptibility

| Variables                  | rs3811464 (cases/controls) |          | rs34767247 (cases/controls) |          | Combined risk genotypes (case/controls) |          |
|----------------------------|-----------------------------|----------|-----------------------------|----------|----------------------------------------|----------|
|                            | GG/GA                       | AA       | AOR (95% CI)$^a$            | P$^a$    | 0                                      | 1-4      |
| Age, month                 |                             |          |                             |          |                                        |          |
| ≤18                        | 181/413                     | 8/12     | 1.50 (0.60-3.75)            | .381     | 126/319                                | 63/106   |
|                            |                             |          |                             |          | 1.51 (1.04-2.19)                        | .031     |
|                            |                             |          |                             |          | 67/186                                 | 122/239  |
|                            |                             |          |                             |          | 1.42 (0.99-2.02)                        | .055     |
| >18                        | 301/627                     | 15/18    | 1.74 (0.87-3.51)            | .120     | 227/502                                | 89/143   |
|                            |                             |          |                             |          | 1.38 (1.01-1.87)                        | .042     |
|                            |                             |          |                             |          | 125/279                                | 191/366  |
|                            |                             |          |                             |          | 1.17 (0.89-1.54)                        | .271     |
| Gender                     |                             |          |                             |          |                                        |          |
| Females                    | 203/439                     | 10/9     | 2.41 (0.97-6.04)            | .060     | 149/340                                | 64/108   |
|                            |                             |          |                             |          | 1.35 (0.94-1.95)                        | .105     |
|                            |                             |          |                             |          | 81/200                                 | 132/248  |
|                            |                             |          |                             |          | 1.31 (0.94-1.83)                        | .109     |
| Males                      | 279/601                     | 13/21    | 1.34 (0.66-2.72)            | .415     | 204/481                                | 88/141   |
|                            |                             |          |                             |          | 1.47 (1.08-2.01)                        | .015     |
|                            |                             |          |                             |          | 111/265                                | 181/357  |
|                            |                             |          |                             |          | 1.21 (0.91-1.61)                        | .184     |
| Sites of origin            |                             |          |                             |          |                                        |          |
| Adrenal gland              | 167/1040                    | 6/30     | 1.28 (0.52-3.13)            | .593     | 124/821                                | 49/249   |
|                            |                             |          |                             |          | 1.31 (0.91-1.88)                        | .147     |
|                            |                             |          |                             |          | 69/465                                 | 104/605  |
|                            |                             |          |                             |          | 1.17 (0.84-1.62)                        | .359     |
| Retroperitoneal            | 138/1040                    | 9/30     | 2.23 (1.04-4.81)            | .041     | 105/821                                | 42/249   |
|                            |                             |          |                             |          | 1.33 (0.90-1.95)                        | .152     |
|                            |                             |          |                             |          | 51/465                                 | 96/605   |
|                            |                             |          |                             |          | 1.44 (1.00-2.07)                        | .048     |
| Mediastinum                | 129/1040                    | 6/30     | 1.67 (0.68-4.11)            | .262     | 94/821                                 | 41/249   |
|                            |                             |          |                             |          | 1.43 (0.96-2.12)                        | .078     |
|                            |                             |          |                             |          | 55/465                                 | 80/605   |
|                            |                             |          |                             |          | 1.13 (0.78-1.62)                        | .528     |
| Others                     | 40/1040                     | 2/30     | 1.67 (0.38-7.27)            | .494     | 27/821                                 | 15/249   |
|                            |                             |          |                             |          | 1.84 (0.96-3.51)                        | .066     |
|                            |                             |          |                             |          | 15/465                                 | 27/605   |
|                            |                             |          |                             |          | 1.38 (0.73-2.63)                        | .326     |
| Clinical stages            |                             |          |                             |          |                                        |          |
| I + II + IV                | 237/1040                    | 13/30    | 1.93 (0.99-3.75)            | .054     | 177/821                                | 73/249   |
|                            |                             |          |                             |          | 1.35 (1.00-1.84)                        | .054     |
|                            |                             |          |                             |          | 87/465                                 | 163/605  |
|                            |                             |          |                             |          | 1.44 (1.08-1.91)                        | .014     |
| III + IV                  | 222/1040                    | 10/30    | 1.59 (0.76-3.31)            | .216     | 162/821                                | 70/249   |
|                            |                             |          |                             |          | 1.43 (1.05-1.97)                        | .025     |
|                            |                             |          |                             |          | 97/465                                 | 135/605  |
|                            |                             |          |                             |          | 1.07 (0.80-1.43)                        | .646     |

Abbreviations: AOR, adjusted odds ratio; CI, confidence interval.

Significance of bold values are the P values less than 0.05 or the 95% CIs excluded 1.

$^a$Adjusted for age and gender, omitting the corresponding stratify factor.
Herein, we undertook a four-centre case-control study to investigate the role of LIN28A polymorphisms on neuroblastoma risk in Chinese children. We are the pioneer in unveiling the association of the rs34787247A allele with an elevated neuroblastoma risk in a Chinese population. At the present, there remain many hidden genetic factors in association with neuroblastoma risk to be discovered to fill up the knowledge gaps. Thus, the identification of more polymorphisms is needed to unearth the full range of neuroblastoma susceptibility variations.

At the present, there remain many hidden genetic factors in association with neuroblastoma risk to be discovered to fill up the knowledge gaps. Thus, the identification of more polymorphisms is needed to unearth the full range of neuroblastoma susceptibility variations. Herein, we undertook a four-centre case-control study to investigate the role of LIN28A polymorphisms on neuroblastoma risk in Chinese children. We are the pioneer in unveiling the association of the rs34787247A allele with an elevated neuroblastoma risk in a Chinese population. LIN28A gene resides on chromosome 1p36.11. Several lines of evidence suggested the roles of LIN28A gene polymorphisms in cancer risk. Zhang et al. found LIN28B rs221636 could decrease the risk of oral cavity cancer in a study of 384 cases and 731 healthy controls, including six SNPs in LIN28 gene. Nevertheless, they failed to detect the association of LIN28A rs4659441 and rs3811463 with oral cavity cancer risk. Permut-Wey et al. observed the predisposing role of rs12728900 and rs11247946 in LIN28A on epithelial ovarian cancer in European ancestry. Sung et al. carried out two genome-wide association studies in East Asia, 5066 breast cancer cases and 4337 controls recruited from Chinese and Koreans. They reported that the 237 SNPs located in microRNA biogenesis pertinent pathway genes had no significant association with breast cancer risk, including SNPs of LIN28A (rs11247954, rs12728900, rs3811463, rs4274112, rs4659441, rs6598964, and rs6683792).

Chen et al. determined the effect of SNPs of LIN28 gene on the breast cancer risk. In analysing five SNPs (rs12122703 A>G, rs3811464 G>A, rs3811463 T>C, rs6697410 T>G) in LIN28, they successfully identified rs3811463 and rs6697410 to be linked to breast cancer risk using a hospital-based case-control study in 1004 cases and 1296 controls. They further conducted a community-based validation study using 511 cases and 645 controls. They validated that the rs3811463-C allele predisposed to an increased risk of breast cancer. Further functional experiments suggested that the rs3811463C allele located near the let-7 binding site of the LIN28 gene. This variant attenuated let-7-induced degradation of LIN28 mRNA, leading to enhanced levels of LIN28 protein, which could, in turn, decrease mature let-7 level, finally alter breast cancer risk. The quite association results of LIN28A SNPs reported by studies implied that the effects of LIN28A on cancer risk would be modified by many factors like ethnicities, sample sizes and cancer types. Therefore, discovering the function of LIN28A SNPs on a particular type of cancer and specific ethnicity is of great necessity.

Given LIN28A’s vital role in malignancies, we undertook this first epidemiological study to outline the correlation of LIN28A polymorphisms and neuroblastoma risk in a Chinese population. Despite the abundance of reports on LIN28A gene variation and cancers, investigations of contribution of LIN28A SNPs to neuroblastoma cancer risks were scarce. Our results thoroughly showed rs34787247A allele could contribute to an increased neuroblastoma risk. Moreover, we also observed an enhanced risk of neuroblastoma in subjects

### Table 3: Association between inferred haplotypes of LIN28A gene and neuroblastoma susceptibility

| Haplotypes | Cases (N = 1010) | Controls (N = 2140) | Crude OR (95% CI) | P | Adjusted OR (95% CI) | P |
|------------|-----------------|--------------------|------------------|---|----------------------|---|
| GTGG       | 642 (63.56)     | 1467 (68.55)       | 1.00             |   | 1.00                 |   |
| GTGA       | 2 (0.20)        | 0 (0.00)           | /                |   | /                    |   |
| GTAG       | 129 (12.77)     | 218 (10.19)        | 1.35 (1.07-1.71) | .013 | 1.35 (1.07-1.72)     | .012 |
| GTAA       | 1 (0.10)        | 0 (0.00)           | /                |   | /                    |   |
| GCGG       | 54 (5.33)       | 123 (5.75)         | 1.00 (0.72-1.40) | .985 | 1.01 (0.72-1.40)     | .977 |
| GCGA       | 2 (0.20)        | 3 (0.14)           | 1.52 (0.25-9.14) | .645 | 1.51 (0.25-9.04)     | .655 |
| GCAG       | 10 (0.99)       | 18 (0.84)          | 1.27 (0.58-2.77) | .548 | 1.27 (0.58-2.76)     | .551 |
| GCAA       | 1 (0.10)        | 1 (0.05)           | 2.29 (0.14-36.59)| .595 | 2.29 (0.14-36.71)    | .558 |
| ATGG       | 64 (6.34)       | 124 (5.79)         | 1.18 (0.86-1.62) | .306 | 1.18 (0.86-1.62)     | .304 |
| ATGA       | 0 (0.00)        | 0 (0.00)           | /                |   | /                    |   |
| ATAG       | 17 (1.68)       | 21 (0.98)          | 1.85 (0.97-3.53) | .062 | 1.85 (0.97-3.53)     | .062 |
| ATAA       | 0 (0)           | 0 (0.00)           | /                |   | /                    |   |
| ACGG       | 56 (5.54)       | 121 (5.65)         | 1.06 (0.76-1.47) | .740 | 1.06 (0.76-1.47)     | .740 |
| ACGA       | 16 (1.58)       | 33 (1.54)          | 1.11 (1.07-3.76) | .055 | 1.11 (1.07-3.76)     | .055 |
| ACAG       | 14 (1.39)       | 10 (0.47)          | 3.20 (1.41-7.24) | .005 | 3.20 (1.41-7.24)     | .005 |
| ACAA       | 2 (0.20)        | 1 (0.05)           | 4.57 (0.41-50.49)| .215 | 4.57 (0.41-50.49)    | .217 |

Abbreviations: CI, confidence interval; OR, odds ratio.
Significance of bold values are the P values less than 0.05 or the 95% CIs excluded 1.

The haplotype order was rs3811464, rs3811463, rs34787247 and rs11247957.

Obtained in logistic regression models with adjustment for age and gender.

### 4 DISCUSSION

At the present, there remain many hidden genetic factors in association with neuroblastoma risk to be discovered to fill up the knowledge gaps. Thus, the identification of more polymorphisms is needed to unearth the full range of neuroblastoma susceptibility variations. Herein, we undertook a four-centre case-control study to investigate the role of LIN28A polymorphisms on neuroblastoma risk in Chinese children. We are the pioneer in unveiling the association of the rs34787247A allele with an elevated neuroblastoma risk in a Chinese population.

LIN28A gene resides on chromosome 1p36.11. Several lines of evidence suggested the roles of LIN28A gene polymorphisms in cancer risk. Zhang et al. found LIN28B rs221636 could decrease the risk of oral cavity cancer in a study of 384 cases and 731 healthy controls, including six SNPs in LIN28 gene. Nevertheless, they failed to detect the association of LIN28A rs4659441 and rs3811463 with oral cavity cancer risk. Permut-Wey et al. observed the predisposing role of rs12728900 and rs11247946 in LIN28A on epithelial ovarian cancer in European ancestry. Sung et al. carried out two genome-wide association studies in East Asia, 5066 breast cancer cases and 4337 controls recruited from Chinese and Koreans. They reported that the 237 SNPs located in microRNA biogenesis pertinent pathway genes had no significant association with breast cancer risk, including SNPs of LIN28A (rs11247954, rs12728900, rs3811463, rs4274112, rs4659441, rs6598964, and rs6683792).
carrying 3 or 1-4 risk genotypes. However, no significant relationship of the rest three variants rs3811464, rs3811463 and rs11247957 was detected.

We carried out a pioneering study on the association between LIN28A gene SNPs and susceptibility to neuroblastoma. Limitations also existed. Firstly, the sample size is not large enough to generate reliable statistics. Some of the results might be merely fortuitous events, particularly the stratification analysis. Secondly, we examined four SNPs in this research. More potential neuroblastoma risk-associated SNPs in the LIN28A gene await to be explored. Thirdly, although the participants were enrolled from four different cities, findings from the restricted Chinese population could not be extrapolated to other ethnicities directly. Lastly, environmental factors were not considered in this study.

In all, we presented a multi-centre case-control study in Chinese children. For the first time, our findings unveiled a contributing role of LIN28A gene SNPs in neuroblastoma risk. In the future, an integrative analysis, covering more profound and specific factors, with environmental factors, genetic-environmental interaction, should be carried out to unearth the aetiology of neuroblastoma.

ACKNOWLEDGEMENTS
This study was supported by grants from the Pearl River S&T Nova Program of Guangzhou (No: 20170010086) and Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease (No: 2019B030301004). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

CONFLICT OF INTEREST
The authors declare no competing financial interests.

AUTHOR’S CONTRIBUTIONS
All authors contributed significantly to this work. RX Hua, L. Yuan, C. Chen, J. Liu, J. Cheng, H. Zhou, J. Zhang, and J. He performed the research study and collected the data; J. He analysed the data; H. Xia, X. Zhang and J. He designed the research study; RX Hua, Z. Zhuo and L. Ge wrote the paper; J Zhu and J. He prepared all the Tables. All authors reviewed the manuscript. In addition, all authors have read and approved the manuscript.

ORCID
Jinhong Zhu https://orcid.org/0000-0002-0408-3101
Huimin Xia https://orcid.org/0000-0002-0103-1672
Jing He https://orcid.org/0000-0002-1954-2892

DATA AVAILABILITY STATEMENT
All the data were available upon request.

REFERENCES
1. Nagaih U. Neuroblastoma cancer in children. J Adv Pharm Technol Res. 2019;10:45.
2. Newman EA, Abdessalam S, Aldrink JH, et al. Update on neuroblastoma. J Pediatr Surg. 2019;54:383-389.
3. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397-411.
4. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106-2120.
5. Meena JP, Gupta AK. Neuroblastoma in a developing country: miles to go. Indian J Pediatr. 2019;86:403-405.
6. Meany HJ. Non-high-risk neuroblastoma: classification and achievements in therapy. Children (Basel). 2019;6:E5.
7. Morgenstern DA, Bagatell R, Cohn SL, et al. The challenge of defining “ultra-high-risk” neuroblastoma. Pediatr Blood Cancer. 2019;66:e27556.
8. Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078.
9. Westermann F, Schwab M. Genetic parameters of neuroblastomas. Cancer Lett. 2002;184:127-147.
10. MacFarland S, Bagatell R. Advances in neuroblastoma therapy. Curr Opin Pediatr. 2019;31:14-20.
11. Bagley AF, Grosshans DR, Philip NV, et al. Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma. Pediatr Blood Cancer. 2019;66(8):e27786.
12. Barr EK, Applebaum MA. Genetic predisposition to neuroblastoma. Children (Basel). 2018;5:E119.
13. Zhong X, Liu Y, Liu H, Zhang Y, Wang L, Zhang H. Identification of potential prognostic genes for neuroblastoma. Front Genet. 2018;9:589.
14. Cook MN, Olshan AF, Guess HA, et al. Maternal medication use and neuroblastoma in offspring. Am J Epidemiol. 2004;159:721-731.
15. Menegaux F, Olshan AF, Neglia JP, Pollock BH, Bondy ML. Day care, childhood infections, and risk of neuroblastoma. Am J Epidemiol. 2004;159:843-851.
16. Ogawa S, Takita J, Sanada M, Hayashi Y. Oncogenic mutations of ALK in neuroblastoma. Cancer Sci. 2011;102:302-308.
17. Aygun Z, Batur S, Emre S, Celkan T, Ozman O, Comunoglu N. Frequency of ALK and GD2 expression in neuroblastoma. Fetal Pediatr Pathol. 2019;38:326-334.
18. Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet. 2004;74:761-764.
19. Diskin SJ, Capasso M, Diamond M, et al. Rare variants in TP53 and susceptibility to neuroblastoma. J Natl Cancer Inst. 2014;106:dju047.
20. Diskin SJ, Capasso M, Schnepp RW, et al. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet. 2012;44:1126-1130.
21. Oldridge DA, Wood AC, Weichert-Leahy N, et al. Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature. 2015;528:418-421.
22. Capasso M, Devoto M, Hou C, et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet. 2009;41:718-723.
23. Capasso M, Diskin S, Cimmino F, et al. Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Res. 2014;74:6913-6924.
24. Capasso M, McDaniel LD, Cimmino F, et al. The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma. J Cell Mol Med. 2017;21:3224-3230.
25. Cimmino F, Avitabile M, Diskin SJ, et al. Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor. Int J Cancer. 2018;143:2828-2837.
26. Shyh-Chang N, Daley GQ. Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell. 2013;12:395-406.
27. Kim JD, Toda C, Ramirez CM, Fernandez-Hernando C, Diano S. Hypothalamic ventromedial Lin28a enhances glucose metabolism in diet-induced obesity. *Diabetes*. 2017;66:2102-2111.
28. Moss EG, Lee RC, Ambros V. The cold shock domain protein LIN-28 controls developmental timing in *C. elegans* and is regulated by the lin-4 RNA. *Cell*. 1997;88:637-646.
29. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. *RNA*. 2008;14:1539-1549.
30. Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. *Nat Cell Biol*. 2008;10:987-993.
31. Heo I, Joo C, Kim YK, et al. TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. *Cell*. 2009;138:696-708.
32. Heo I, Joo C, Cho J, Ha M, Han J, Kim VN. Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. *Mol Cell*. 2008;32:276-284.
33. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer Res*. 2004;64:3753-3756.
34. Yu L, Jiang Y, Tang B. Lin28a functionally modulates bupivacaine-induced dorsal root ganglion neuron apoptosis through TrkA activation. *Biomed Pharmacother*. 2018;98:63-68.
35. Viswanathan SR, Powers JT, Einhorn W, et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. *Cancer Res*. 2011;71:3896-3903.
36. Sung H, Zhang B, Choi JY, et al. Common genetic variants in the microRNA biogenesis pathway are not associated with breast cancer risk in Asian women. *Cancer Epidemiol Biomarkers Prev*. 2012;21:1385-1387.
37. Chen AX, Yu KD, Fan L, et al. Germline genetic variants disturbing the Let-7/LIN28 double-negative feedback loop alter breast cancer susceptibility. *PLoS Genet*. 2011;7:e1002259.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.